Neurofibromatosis 2

Neurofibromatosis 2 (NF2) is characterized by benign tumors on the nerve that carries sound and balance information from the inner ear to the brain. These tumors affect both ears, often leading to partial or complete hearing loss. People with NF2 may also develop other types of benign brain or spinal tumors. 
Quick Reference
Test Code 9024
Turnaround Time (TAT) 14-21 days
Number of Genes 1

Ordering Options

We offer family variant testing at no additional cost

for all blood relatives of patients who undergo full single gene sequencing or multigene panel testing* at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant. No-cost testing of blood relatives must be completed within 90 days of the original Ambry report date.

Order Now

*excludes Secondary Findings and SNP Array tests


Mutation Detection Rate

This test can detect >99.9% of described mutations in NF2, when present (analytic sensitivity).

Test Description

NF2 coding exons and well into the 5’ and 3’ ends of all the introns and untranslated regions are analyzed by sequencing. Gross deletion/duplication analysis determines gene copy number for coding exons. Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using standardized methodology and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology, using long biotinylated oligonucleotide probes followed by polymerase chain reaction (PCR) and next generation sequencing (NGS). Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Potentially homozygous variants, variants in regions complicated by pseudogene interference, and variant calls not satisfying depth of coverage and variant allele frequency quality thresholds are verified by Sanger sequencing. Gross deletion/duplication analysis of NF2 using the multiplex ligation-dependent probe amplification (MLPA) kit is also performed.

View Full Menu

Search Results

Start your search...